| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 12
| Issue : 5 | Page : 54-56 |
|
|
S-1 combined with cisplatin chemotherapy for advanced gastric cancer
Chen Weidong, Xia Lijun
Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000, PR China
Correspondence Address:
Xia Lijun
Department of Clinical Pharmacy, Lishui People's Hospital of Zhejiang Province, Lishui 323000
PR China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.191631
|
|
|
Objective: To observe the short-term efficacy and safety of S-1 combined with cisplatin (DDP) chemotherapy for advanced gastric cancer (AGC).
Materials and Methods: Sixty-six patients were diagnosed with AGC and were admitted to our department from February 2012 to January 2015 and retrospectively analyzed. Of these patients, 31 (experimental group) underwent S-1 combined with DDP chemotherapy and 35 received oxaliplatin combined with tegafur and calcium folinate chemotherapy regimen (control group). The chemotherapy regimen for the experimental group included S-1, 60 mg bid on d1–d14 and 60 mg/m 2 DDP by intravenous dripping on d1–d3, with 4 weeks in a cycle. The chemotherapy regimen for the control group consisted of 130 mg/m 2 oxaliplatin by intravenous dripping, d1; 600 mg/m 2 tegafur by intravenous dripping on d1–d5; and 120 mg/m 2 calcium folinate by intravenous dripping on d1–d5, with 3 weeks in a cycle. The efficacies and adverse effects of the two regimens were assessed after three cycles.
Results: After three cycles, the objective response rates of the experimental and control groups were 41.94% and 42.86%, without significantly difference (P > 0.05), respectively. However, the incidence rate of adverse drug reactions in Grades 3–4 in the experimental group was significantly lower than that of control group (P < 0.05).
Conclusion: The short-term efficacy of primary S-1 with DDP chemotherapy for AGC is relatively satisfactory with less adverse effects. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
